Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032524 | 0.88 | NAMPT (0.48) | NAMPTTHRBLMNAMAPTSMN1; SMN2 | |
| SCHEMBL7078296 | 0.87 | BTK (0.45) | THRBMAPTSMN1; SMN2BTKALDH1A1 | |
| SCHEMBL7030868 | 0.81 | NAMPT (0.49) | NAMPTBTK | |
| SCHEMBL7028452 | 0.79 | NPC1 (0.47) | MAPTSMN1; SMN2ALDH1A1MGLLMAOB | |
| SCHEMBL5234339 | 0.78 | MGLL (0.46) | MAPTSMN1; SMN2ALDH1A1MGLLMAOB | |
| SCHEMBL5833407 | 0.76 | HTR6 (0.50) | NAMPT | |
| SCHEMBL7002216 | 0.74 | MGLL (0.42) | MAPTSMN1; SMN2ALDH1A1MGLLMAOB | |
| SCHEMBL6465956 | 0.74 | NPY2R (0.54) | LMNAMAPTSMN1; SMN2TGM2ALDH1A1 | |
| SCHEMBL18786518 | 0.72 | MGLL (0.58) | MAPTSMN1; SMN2ALDH1A1MGLLMAOB | |
| SCHEMBL7212293 | 0.71 | MGLL (0.43) | MAPTSMN1; SMN2ALDH1A1MGLLMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003515539-A | — | — | 2003-05-07 | — | — | JP | claimed |
| EP-1237895-A2 | PHOSPHORYLATION OF TERMINAL PRIMARY ALCOHOL GROUPS | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | claimed |
| WO-2001040236-A2 | PHOSPHORYLATION OF TERMINAL PRIMARY ALCOHOL GROUPS | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | claimed |
| US-7087629-B2 | Useful activity against Gram-positive pathogens and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used beta-lactams | ASTRAZENECA AB (SE) | 2006-08-08 | — | — | US | disclosed |
| US-6734200-B1 | ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | disclosed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
| WO-2002096916-A1 | PROCESS FOR PHOSPHORYLATION | ASTRAZENECA AB (SE) | 2002-12-05 | — | — | WO | disclosed |
| EP-1237895-A2 | PHOSPHORYLATION OF TERMINAL PRIMARY ALCOHOL GROUPS | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040236-A2 | PHOSPHORYLATION OF TERMINAL PRIMARY ALCOHOL GROUPS | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| EP-1082323-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca UK Limited (GB) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999064417-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | NAMPT 4776/4885THRB 1953/4885LMNA 3058/4885 |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | HDHD5, CYP8B1, LSS | NAMPT 4760/4885THRB 2245/4885LMNA 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.